Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: Where we stand and where we go

Thomas Gevaert, Alessia Cimadamore, Markus Eckstein, Marina Scarpelli, Antonio Lopez-Beltran, Liang Cheng, Rodolfo Montironi

Research output: Contribution to journalReview article

Original languageEnglish (US)
Pages (from-to)2199-2202
Number of pages4
JournalFuture Oncology
Volume15
Issue number19
DOIs
StatePublished - Jul 2019

Keywords

  • PD-L1
  • atezolizumab
  • basal-type
  • genitourinary tumors
  • immunotherapy
  • luminal-type
  • lymphocytes
  • microbiome
  • urothelial carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Gevaert, T., Cimadamore, A., Eckstein, M., Scarpelli, M., Lopez-Beltran, A., Cheng, L., & Montironi, R. (2019). Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: Where we stand and where we go. Future Oncology, 15(19), 2199-2202. https://doi.org/10.2217/fon-2019-0217